Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MMV665924
- Development stage
- Preclinical
- Lead developer
- Medicines for Malaria Venture
- Modality
- Small Molecules
01
Overview
MMV665924 is a small molecule antimalarial compound identified from the Medicines for Malaria Venture (MMV) Malaria Box. It acts as an inhibitor of *Plasmodium falciparum* acyl-CoA synthetase 10 (PfACS10), an essential enzyme involved in activating scavenged fatty acids for lipid biosynthesis. Inhibition of PfACS10 by MMV665924 disrupts triglyceride formation, leading to a reduction in triacylglycerols and a buildup of lipid precursors, which ultimately kills the asexual blood-stage parasites. Resistance to MMV665924 is mediated by mutations in PfACS10 as well as mutations in the non-essential acyl-CoA synthetase 11 (PfACS11), which acts as a resistance mediator.
- Other names
- [2-(4-chlorophenyl)cyclopropyl](4-methoxyphenyl)methanone
Beyond the preview
Go deeper on MMV665924.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMV665924.